Harlan F. Weisman - Dec 3, 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc. (TFFP)

Role: President and CEO, Director
Signature: /s/ Harlan F. Weisman, by Kirk Allen Coleman, as Attorney-in-Fact
Stock symbol: TFFP
Transactions as of: Dec 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/6/2022, 08:39 PM
Previous filing: May 20, 2022
Next filing: Dec 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TFFP	Stock Options (Right to Buy)	Award	$0	+1.79M		$0.00	1.79M	Dec 3, 2022	Common Stock	1.79M	$1.19	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Options shall vest during the period of Dr. Weisman's service as CEO of the Company as follows: Options to purchase 298,750 shares of Common Stock ("Six Month Options") shall vest upon the six-month anniversary of the date of grant and Options to purchase 49,790 shares of Common Stock shall vest in 30 monthly installments commencing on the seven-month anniversary of the date of grant. In the event of the Company's termination of Dr. Weisman's service as CEO ("Termination of Service") as a result of hiring a permanent CEO all unvested Options shall immediately expire.

Content

The Options shall vest during the period of Dr. Weisman's service as CEO of the Company as follows: Options to purchase 298,750 shares of Common Stock ("Six Month Options") shall vest upon the six-month anniversary of the date of grant and Options to purchase 49,790 shares of Common Stock shall vest in 30 monthly installments commencing on the seven-month anniversary of the date of grant. In the event of the Company's termination of Dr. Weisman's service as CEO ("Termination of Service") as a result of hiring a permanent CEO all unvested Options shall immediately expire.